Anna Marie Hansen Counselor Medicare: Not Enrolled in Medicare Practice Location: 5186 Scoresby Ave, Iona, ID 83427 Phone: 208-520-8392 |
News Archive
Two experimental drug approaches that target vulnerabilities in cancer cell metabolism may extend survival and enhance the effectiveness of standard chemotherapies for a highly aggressive type of pediatric brain cancer.
Many patients with rare, fast-growing neuroendocrine tumors respond well to a common immunotherapy drug combination, according to the first peer-reviewed publication out of DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, a unique rare cancer clinical trial.
Kaiser Health News staff writer Christopher Weaver writes: "When it comes to health policy, few ideas find as much bipartisan support as the notion that widespread adoption of health information technology could improve medical care and save money.
Scientists have performed a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, called NitroSynapsin, largely corrected electrical, behavioral and brain abnormalities in the mice.
Patients with Crohn's disease of the colon have one copy less than healthy persons of the beta-defensin 2 gene, a gene coding for an important defense molecule of the body.
› Verified 9 days ago